Verastem, Inc. (VSTM)
VSTM Stock Price Chart
Explore Verastem, Inc. interactive price chart. Choose custom timeframes to analyze VSTM price movements and trends.
VSTM Company Profile
Discover essential business fundamentals and corporate details for Verastem, Inc. (VSTM) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
27 Jan 2012
Employees
78.00
Website
https://www.verastem.comCEO
Daniel W. Paterson
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
VSTM Financial Timeline
Browse a chronological timeline of Verastem, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 5 Nov 2025
EPS estimate is -$0.71.
Earnings released on 7 Aug 2025
EPS came in at -$0.39 surpassing the estimated -$0.85 by +54.12%, while revenue for the quarter reached $2.14M , missing expectations by -62.49%.
Earnings released on 13 May 2025
EPS came in at -$0.96 falling short of the estimated -$0.72 by -33.33%.
Earnings released on 20 Mar 2025
EPS came in at -$1.33 falling short of the estimated -$0.81 by -64.20%, while revenue for the quarter reached -$9.98M , missing expectations by -6.75K%.
Earnings released on 6 Nov 2024
EPS came in at -$0.60 surpassing the estimated -$0.71 by +15.49%.
Earnings released on 8 Aug 2024
EPS came in at -$0.31 surpassing the estimated -$1.06 by +70.75%, while revenue for the quarter reached $10.00M , beating expectations by +19.90K%.
Earnings released on 9 May 2024
EPS came in at -$1.26 falling short of the estimated -$1.16 by -8.62%.
Earnings released on 14 Mar 2024
EPS came in at -$1.02 falling short of the estimated -$0.82 by -24.39%, while revenue for the quarter reached $114.00K , missing expectations by -97.76%.
Earnings released on 8 Nov 2023
EPS came in at -$0.75 surpassing the estimated -$0.92 by +18.48%.
Earnings released on 8 Aug 2023
EPS came in at -$1.37 falling short of the estimated -$1.13 by -21.24%.
Stock split effective on 1 Jun 2023
Shares were split 1 : 12 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 9 May 2023
EPS came in at -$0.96 surpassing the estimated -$1.08 by +11.11%.
Earnings released on 14 Mar 2023
EPS came in at -$0.96 falling short of the estimated $0.10 by -1.06K%, while revenue for the quarter reached $2.60M .
Earnings released on 3 Nov 2022
EPS came in at -$1.08 surpassing the estimated -$1.44 by +25.00%.
Earnings released on 8 Aug 2022
EPS came in at -$1.44 falling short of the estimated -$1.32 by -9.09%.
Earnings released on 9 May 2022
EPS came in at -$1.08 falling short of the estimated -$0.96 by -12.50%, while revenue for the quarter reached $2.60M , beating expectations by +73.07%.
Earnings released on 28 Mar 2022
EPS came in at -$1.08 falling short of the estimated -$0.96 by -12.50%, while revenue for the quarter reached $545.00K , beating expectations by +990.00%.
Earnings released on 4 Nov 2021
EPS came in at -$1.56 falling short of the estimated -$1.08 by -44.44%, while revenue for the quarter reached $2.00K , beating expectations by +9.11%.
Earnings released on 2 Aug 2021
EPS came in at -$1.20 falling short of the estimated -$1.08 by -11.11%, while revenue for the quarter reached $500.00K , beating expectations by +900.00%.
Earnings released on 11 May 2021
EPS came in at -$1.08 matching the estimated -$1.08, while revenue for the quarter reached $1.01M , meeting expectations.
Earnings released on 18 Mar 2021
EPS came in at -$1.44 , while revenue for the quarter reached $506.00K .
Earnings released on 9 Nov 2020
EPS came in at $0.96 falling short of the estimated $3.36 by -71.43%, while revenue for the quarter reached $78.65M , missing expectations by -9.09%.
VSTM Stock Performance
Access detailed VSTM performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.